Research analysts covering PRF Technologies.
Recent press releases and 8-K filings for PRFX.
PRF Technologies Files First Patent Application for Solar Plant Micro-Climate Forecast Modeling
PRFX
New Projects/Investments
- PRF Technologies Ltd. (formerly PainReform) has filed its first patent application for solar plant micro-climate forecast modeling.
- This patent covers proprietary methods for solar plant-level micro-climate modeling designed to significantly improve the accuracy of solar energy production forecasts in competitive electric utility markets.
- The technology, named DeepSolar Predict, aims to enhance revenue optimization, reduce penalty risks, and improve market performance for utility-scale solar assets by providing more precise short-term and intraday forecasts.
Jan 20, 2026, 2:07 PM
PRF Technologies Files Patent Application for Solar Plant Micro-Climate Forecast Modeling
PRFX
New Projects/Investments
Product Launch
- PRF Technologies Ltd. (Nasdaq: PRFX) has filed a patent application covering proprietary methods for solar plant–level micro-climate modeling.
- This patent aims to protect the core intellectual property underlying DeepSolar Predict, PRF Technologies’ solar forecasting software platform.
- The technology is designed to significantly improve the accuracy of solar energy production forecasts by capturing highly localized conditions, which can lead to reduced financial penalties and enhanced revenue for solar asset owners.
- The patent filing follows PRF Technologies' acceptance into the NVIDIA Connect Program.
Jan 20, 2026, 2:05 PM
PRFX: PainReform Ltd. Changes Name to PRF Technologies Ltd.
PRFX
New Projects/Investments
- PainReform Ltd. officially changed its name to PRF Technologies Ltd. following shareholder approval at its Annual General Meeting on January 6, 2026.
- The company's Nasdaq ticker symbol will remain PRFX.
- This name change reflects a strategic shift to a diversified innovation platform, moving beyond a single-product focus to include specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics.
- The company has broadened its portfolio over the past 18 months, establishing new growth platforms such as LayerBio for ophthalmology and DeepSolar for AI-driven solar analytics, in addition to advancing its PRF-110 non-opioid pain therapy.
Jan 15, 2026, 9:10 PM
PRF Technologies Ltd. Announces Corporate Name Change and Strategic Expansion
PRFX
New Projects/Investments
Proxy Vote Outcomes
- PainReform Ltd. has changed its corporate name to PRF Technologies Ltd. following shareholder approval at its Annual General Meeting on January 6, 2026, while its Nasdaq ticker symbol will remain PRFX.
- The name change reflects the company's evolution into a diversified innovation platform encompassing specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics, moving beyond its original single-product focus.
- The company has expanded its pharmaceutical platform through LayerBio, entering the ophthalmology market with OcuRing™-K, a non-opioid, sustained-release ocular therapy for post-cataract surgery pain and inflammation.
- PRF has also established DeepSolar, an AI-driven solar analytics and digital asset-management business, which has progressed into early commercial deployment.
Jan 15, 2026, 9:05 PM
PainReform Completes Acquisition of LayerBio Inc.
PRFX
M&A
New Projects/Investments
- PainReform Ltd. completed the acquisition of 51% of LayerBio Inc. on August 13, 2025, for an initial cash consideration of $600 thousand (net of a $50 thousand bridge loan).
- The acquisition includes a potential additional investment of up to $2.4 million contingent on LayerBio achieving specified clinical milestones related to its planned Phase II trial.
- The total purchase consideration for LayerBio was $1,531 thousand, which led to the recognition of $185 thousand in goodwill and $872 thousand in intangible assets.
- As of June 30, 2025, the unaudited pro forma combined financial information shows total assets of $12,253 thousand, total liabilities of $2,879 thousand, and total shareholders' equity of $8,443 thousand.
Jan 7, 2026, 9:15 PM
PainReform Commences Development for OcuRing™-K Phase II Trial
PRFX
New Projects/Investments
Product Launch
- PainReform Ltd. announced the commencement of its development plan for OcuRing™-K, LayerBio’s drop-less sustained-release ocular therapy, with work progressing toward a Phase II clinical trial.
- OcuRing™-K is designed to deliver controlled, site-specific release of ketorolac following cataract surgery, aiming to address limitations of traditional eye-drop regimens.
- This initiative targets the multi-billion-dollar global cataract surgery market, which sees approximately 4.5 million surgeries annually in the United States.
- The development follows PainReform's majority investment in LayerBio and the integration of OcuRing-K into its pharmaceutical development portfolio.
Dec 2, 2025, 2:40 PM
PainReform Ltd. Schedules Annual General Meeting to Vote on Reverse Split, Name Change, and Capital Increase
PRFX
Delisting/Listing Issues
New Projects/Investments
Executive Compensation
- PainReform Ltd. will hold an Annual General Meeting on December 30, 2025, to vote on several key proposals.
- Shareholders will vote on a 1-to-5 reverse share split to assist in maintaining compliance with Nasdaq Capital Market listing requirements, with potential delisting if not approved.
- The company proposes to change its name from "Painreform Ltd." to "PRF Ltd." to reflect an expanded business model that includes the DeepSolar AI-driven solar analytics platform.
- Other proposals include an increase in authorized share capital by 50,000,000 shares, bringing the total to 60,000,000 ordinary shares, and the grant of 15,000 options to director Asaf Shavit.
Nov 25, 2025, 9:15 PM
PainReform's DeepSolar Unit Progresses with DeepSolar Predict in NVIDIA Connect Program
PRFX
New Projects/Investments
Product Launch
- PainReform Ltd.'s DeepSolar business unit is developing "DeepSolar Predict," an AI-based forecasting module within the NVIDIA Connect Program.
- DeepSolar Predict is designed to enhance weather-driven energy production forecasts for utility-scale solar owners, aiming to reduce imbalance risks and improve profitability.
- The company announced progress toward its first pilot projects with prospective customers, marking a step toward commercial deployment.
- PainReform operates with a dual business model, focusing on pharmaceutical reformulation and AI-driven energy optimization via DeepSolar.
Nov 5, 2025, 1:45 PM
PainReform Reports Reduced Net Loss and Strategic Acquisitions in H1 2025
PRFX
Earnings
M&A
New Projects/Investments
- PainReform reduced its net loss to approximately $2.3 million for the six months ended June 30, 2025, a significant improvement from $12.8 million in the prior-year period, and reported $3.5 million in cash and cash equivalents with $1.5 million in positive working capital as of June 30, 2025.
- The company completed a majority investment in LayerBio in August 2025, acquiring OcuRing™-K, a breakthrough dropless cataract therapy targeting a $9 billion global market.
- PainReform also acquired the DeepSolar business operations in March 2025, which has since secured its first commercial agreement with Econergy for a 92MW project, transitioning from pilot to initial commercial deployment.
- The company has not generated significant revenue to date and explicitly states it does not have sufficient resources to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern.
Oct 1, 2025, 1:29 PM
PainReform Provides Business Update for H1 2025
PRFX
Earnings
M&A
New Projects/Investments
- PainReform reduced its net loss to $2.3 million for the six months ended June 30, 2025, a significant decrease from $12.8 million in the prior-year period, and maintained $3.5 million in cash and $1.5 million in positive working capital as of June 30, 2025.
- The company completed a majority investment in LayerBio in August 2025, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9 billion global market.
- The DeepSolar division achieved key milestones, including the completion of the Smart Energy Management app, acceptance into the NVIDIA Connect Program, and the successful transition of a 92MW pilot project with Econergy into its first commercial agreement.
Oct 1, 2025, 1:27 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more